Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of denikitug alone or with nivolumab or chemotherapy in HER2-negative advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma
CTR20263204Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of denikitug in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Gilead Sciences. Started Aug 2026; status: terminated.
02
Drugs
denikitug
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20263204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263204.